ICP B05
Alternative Names: CM-369; ICP-B05Latest Information Update: 26 Apr 2023
At a glance
- Originator Tiannuojiancheng Pharma
- Developer InnoCare Pharma; Tiannuojiancheng Pharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CCR8 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haematological malignancies; Solid tumours
Most Recent Events
- 31 Mar 2023 Preclinical trials in Haematological malignancies in China (Parenteral) before March 2023 (InnoCare Pharma pipeline, April 2023)
- 31 Mar 2023 InnoCare Pharma receives IND approval for ICP B05 in Haematological malignancies in China (InnoCare Pharma pipeline, April 2023)
- 23 Feb 2023 Phase-I clinical trials in Haematological malignancies (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in China (Parenteral) (NCT05690581)